OncoMatch/Clinical Trials/NCT01344200
CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children
Is NCT01344200 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Celecoxib for pharmacokinetics of celecoxib in children.
Treatment: Celecoxib — Celecoxib is effective for reducing postoperative pain in adults. Children use celecoxib more rapidly than adults and require higher doses. Celecoxib is partially metabolized in the liver by a certain enzyme. A person's genetic variation of this enzyme can influence how well their body uses Celecoxib. Furthermore, Celecoxib down-regulates P-glycoprotein (P-gp), a drug efflux transporter located at the blood brain barrier responsible for central nervous system (CNS) extrusion of ondansetron and possibly fentanyl; therefore celecoxib may augment the CNS effects of these drugs. Understanding the blood and cerebrospinal fluid (CSF) profile of celecoxib in children and the influence of genetics on metabolism would help to develop appropriate celecoxib dosing in children for various treatment options.
Check if I qualifyExtracted eligibility criteria
Lab requirements
Kidney function
serum creatinine > 2 x unl within 30 days
Liver function
alt > 2 x unl, ast > 2 x unl, total & direct bilirubin > 2 x unl within 30 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify